Maurizio Zangari
Concepts (495)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 148 | 2024 | 2954 | 10.400 |
Why?
| Thalidomide | 33 | 2016 | 377 | 3.060 |
Why?
| Boronic Acids | 17 | 2013 | 182 | 2.920 |
Why?
| Pyrazines | 17 | 2013 | 187 | 2.920 |
Why?
| Hematopoietic Stem Cell Transplantation | 22 | 2024 | 567 | 2.100 |
Why?
| Bone Marrow | 17 | 2022 | 363 | 1.950 |
Why?
| Venous Thrombosis | 8 | 2009 | 90 | 1.760 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 31 | 2024 | 990 | 1.740 |
Why?
| Paraproteinemias | 7 | 2022 | 72 | 1.660 |
Why?
| Angiogenesis Inhibitors | 12 | 2009 | 188 | 1.570 |
Why?
| Humans | 162 | 2024 | 50208 | 1.420 |
Why?
| Protease Inhibitors | 7 | 2011 | 58 | 1.390 |
Why?
| Chromosomes, Human, Pair 1 | 7 | 2023 | 93 | 1.350 |
Why?
| Proteasome Inhibitors | 6 | 2016 | 104 | 1.300 |
Why?
| Prognosis | 40 | 2024 | 1954 | 1.230 |
Why?
| Middle Aged | 66 | 2024 | 12206 | 1.210 |
Why?
| Antineoplastic Agents | 20 | 2024 | 1186 | 1.200 |
Why?
| Aged | 63 | 2024 | 9405 | 1.200 |
Why?
| Alkaline Phosphatase | 7 | 2020 | 95 | 1.190 |
Why?
| Neoplasm, Residual | 6 | 2022 | 165 | 1.160 |
Why?
| Transplantation, Autologous | 30 | 2024 | 469 | 1.140 |
Why?
| Thrombosis | 6 | 2013 | 248 | 1.080 |
Why?
| Bone Remodeling | 3 | 2016 | 149 | 1.070 |
Why?
| Bone Diseases | 2 | 2021 | 99 | 1.050 |
Why?
| Antibodies, Bispecific | 5 | 2024 | 69 | 1.030 |
Why?
| Osteogenesis | 4 | 2018 | 353 | 0.960 |
Why?
| Male | 73 | 2024 | 25399 | 0.960 |
Why?
| Female | 72 | 2024 | 26635 | 0.940 |
Why?
| Immunologic Factors | 5 | 2016 | 114 | 0.930 |
Why?
| Gene Expression Profiling | 21 | 2023 | 1037 | 0.900 |
Why?
| Anticoagulants | 6 | 2009 | 253 | 0.860 |
Why?
| Peripheral Blood Stem Cell Transplantation | 6 | 2012 | 53 | 0.850 |
Why?
| Melphalan | 12 | 2016 | 174 | 0.840 |
Why?
| Neoplasms, Plasma Cell | 4 | 2024 | 37 | 0.830 |
Why?
| Activated Protein C Resistance | 4 | 2011 | 10 | 0.810 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 8 | 2024 | 115 | 0.790 |
Why?
| Parathyroid Hormone | 4 | 2018 | 147 | 0.770 |
Why?
| Venous Thromboembolism | 3 | 2011 | 68 | 0.760 |
Why?
| Antibodies, Monoclonal | 4 | 2022 | 460 | 0.750 |
Why?
| Adult | 41 | 2024 | 13324 | 0.730 |
Why?
| Durapatite | 1 | 2020 | 24 | 0.720 |
Why?
| Disease-Free Survival | 21 | 2019 | 454 | 0.690 |
Why?
| Gene Amplification | 1 | 2019 | 57 | 0.690 |
Why?
| Survival Rate | 21 | 2020 | 901 | 0.680 |
Why?
| Thromboembolism | 3 | 2009 | 54 | 0.680 |
Why?
| Neoplasm Proteins | 7 | 2020 | 324 | 0.680 |
Why?
| Dexamethasone | 14 | 2024 | 430 | 0.670 |
Why?
| Myeloablative Agonists | 4 | 2012 | 30 | 0.670 |
Why?
| Retrospective Studies | 24 | 2024 | 6134 | 0.630 |
Why?
| Gene Expression Regulation, Neoplastic | 12 | 2021 | 828 | 0.630 |
Why?
| Bone and Bones | 4 | 2021 | 475 | 0.630 |
Why?
| Factor V | 4 | 2011 | 11 | 0.620 |
Why?
| Oligopeptides | 3 | 2018 | 91 | 0.620 |
Why?
| Spinal Fractures | 1 | 2018 | 38 | 0.620 |
Why?
| Aged, 80 and over | 20 | 2024 | 3154 | 0.620 |
Why?
| Thymus Gland | 1 | 2018 | 41 | 0.610 |
Why?
| Treatment Outcome | 32 | 2024 | 5155 | 0.600 |
Why?
| Stem Cell Transplantation | 12 | 2024 | 182 | 0.600 |
Why?
| Parathyroidectomy | 1 | 2018 | 45 | 0.600 |
Why?
| Thyroidectomy | 1 | 2018 | 60 | 0.590 |
Why?
| Translocation, Genetic | 8 | 2021 | 264 | 0.590 |
Why?
| Disease Progression | 16 | 2023 | 831 | 0.590 |
Why?
| Clinical Trials as Topic | 9 | 2022 | 466 | 0.580 |
Why?
| Chromosome Aberrations | 11 | 2023 | 297 | 0.570 |
Why?
| Calcification, Physiologic | 1 | 2017 | 41 | 0.570 |
Why?
| Follow-Up Studies | 22 | 2024 | 2190 | 0.560 |
Why?
| Pelvis | 1 | 2017 | 67 | 0.560 |
Why?
| Osteoblasts | 6 | 2020 | 450 | 0.550 |
Why?
| Thrombophilia | 4 | 2009 | 18 | 0.540 |
Why?
| Risk Factors | 22 | 2021 | 3629 | 0.530 |
Why?
| Survival Analysis | 13 | 2021 | 666 | 0.520 |
Why?
| Tumor Microenvironment | 5 | 2024 | 233 | 0.520 |
Why?
| Chromosome Deletion | 6 | 2023 | 140 | 0.500 |
Why?
| Drug Resistance, Neoplasm | 7 | 2015 | 314 | 0.500 |
Why?
| Plasma Cells | 9 | 2023 | 223 | 0.500 |
Why?
| B-Cell Maturation Antigen | 6 | 2024 | 91 | 0.480 |
Why?
| Neoplasms | 3 | 2009 | 1249 | 0.480 |
Why?
| Animals | 19 | 2024 | 13246 | 0.480 |
Why?
| Transplantation Conditioning | 7 | 2019 | 84 | 0.470 |
Why?
| Neoplasm Recurrence, Local | 7 | 2024 | 613 | 0.460 |
Why?
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2013 | 24 | 0.450 |
Why?
| Polycythemia Vera | 1 | 2013 | 6 | 0.440 |
Why?
| Hemostasis | 3 | 2008 | 55 | 0.430 |
Why?
| Neovascularization, Pathologic | 4 | 2009 | 162 | 0.420 |
Why?
| Mutation | 6 | 2022 | 1294 | 0.410 |
Why?
| Combined Modality Therapy | 17 | 2024 | 636 | 0.410 |
Why?
| Neutropenia | 2 | 2023 | 115 | 0.400 |
Why?
| Hematopoietic Stem Cells | 2 | 2012 | 184 | 0.380 |
Why?
| Bone Neoplasms | 2 | 2010 | 183 | 0.370 |
Why?
| Amyloidosis | 3 | 2009 | 81 | 0.360 |
Why?
| Evolution, Molecular | 2 | 2021 | 99 | 0.360 |
Why?
| Doxorubicin | 7 | 2009 | 239 | 0.360 |
Why?
| Immunotherapy, Adoptive | 4 | 2024 | 157 | 0.350 |
Why?
| Anti-Anxiety Agents | 1 | 2009 | 35 | 0.340 |
Why?
| Mice | 11 | 2024 | 5759 | 0.340 |
Why?
| In Situ Hybridization, Fluorescence | 7 | 2023 | 259 | 0.330 |
Why?
| Kaplan-Meier Estimate | 10 | 2019 | 465 | 0.330 |
Why?
| Hemorrhagic Disorders | 1 | 2009 | 5 | 0.330 |
Why?
| Cryoglobulinemia | 1 | 2008 | 13 | 0.320 |
Why?
| Biopsy, Needle | 1 | 2009 | 181 | 0.320 |
Why?
| Pain | 2 | 2009 | 381 | 0.320 |
Why?
| Analgesics | 1 | 2009 | 101 | 0.310 |
Why?
| Recurrence | 11 | 2024 | 662 | 0.310 |
Why?
| Pulmonary Embolism | 1 | 2009 | 97 | 0.310 |
Why?
| Collagen | 2 | 2020 | 207 | 0.310 |
Why?
| Risk Assessment | 7 | 2023 | 1262 | 0.300 |
Why?
| Hematologic Neoplasms | 2 | 2022 | 99 | 0.290 |
Why?
| Cell Line, Tumor | 4 | 2023 | 1416 | 0.290 |
Why?
| Farnesyltranstransferase | 1 | 2006 | 5 | 0.290 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2004 | 32 | 0.280 |
Why?
| Osteolysis | 2 | 2022 | 75 | 0.280 |
Why?
| Waldenstrom Macroglobulinemia | 2 | 2022 | 40 | 0.280 |
Why?
| Pyrroles | 2 | 2004 | 69 | 0.280 |
Why?
| Risk | 4 | 2014 | 324 | 0.280 |
Why?
| Cell Differentiation | 4 | 2022 | 650 | 0.270 |
Why?
| Neoplasms, Second Primary | 2 | 2024 | 78 | 0.270 |
Why?
| Sirolimus | 1 | 2006 | 62 | 0.270 |
Why?
| Cell Proliferation | 8 | 2023 | 1013 | 0.270 |
Why?
| Time Factors | 11 | 2021 | 2922 | 0.270 |
Why?
| Logistic Models | 5 | 2018 | 889 | 0.270 |
Why?
| Signal Transduction | 6 | 2021 | 1622 | 0.260 |
Why?
| Chromosomes, Human, Pair 17 | 2 | 2017 | 36 | 0.260 |
Why?
| Fluorodeoxyglucose F18 | 4 | 2021 | 194 | 0.240 |
Why?
| Plasmacytoma | 2 | 2020 | 42 | 0.240 |
Why?
| Enoxaparin | 1 | 2004 | 27 | 0.240 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 47 | 0.240 |
Why?
| Remission Induction | 10 | 2021 | 207 | 0.240 |
Why?
| Indoles | 2 | 2004 | 278 | 0.230 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2004 | 202 | 0.230 |
Why?
| Prospective Studies | 9 | 2019 | 2379 | 0.220 |
Why?
| Blood Coagulation | 1 | 2003 | 56 | 0.220 |
Why?
| Positron-Emission Tomography | 3 | 2022 | 294 | 0.210 |
Why?
| Bone Resorption | 2 | 2022 | 302 | 0.210 |
Why?
| Immunoglobulin Light Chains | 2 | 2017 | 82 | 0.210 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 79 | 0.210 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2012 | 550 | 0.200 |
Why?
| Hematopoietic Stem Cell Mobilization | 3 | 2008 | 57 | 0.200 |
Why?
| Immunoconjugates | 1 | 2022 | 38 | 0.200 |
Why?
| Drug Approval | 1 | 2022 | 47 | 0.200 |
Why?
| Cell Cycle | 2 | 2021 | 232 | 0.200 |
Why?
| Hemorrhage | 3 | 2009 | 197 | 0.200 |
Why?
| Chromosomal Instability | 2 | 2019 | 16 | 0.200 |
Why?
| Lymphoma, B-Cell | 1 | 2022 | 63 | 0.200 |
Why?
| Epigenomics | 1 | 2021 | 68 | 0.190 |
Why?
| Chromosomes, Human, Pair 13 | 5 | 2008 | 38 | 0.190 |
Why?
| Patient Participation | 1 | 2022 | 66 | 0.190 |
Why?
| SOXC Transcription Factors | 1 | 2021 | 13 | 0.190 |
Why?
| Arkansas | 5 | 2021 | 1985 | 0.190 |
Why?
| T-Lymphocytes | 4 | 2024 | 339 | 0.190 |
Why?
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 124 | 0.190 |
Why?
| Odontoblasts | 1 | 2020 | 4 | 0.180 |
Why?
| Calcium Phosphates | 1 | 2020 | 5 | 0.180 |
Why?
| HL-60 Cells | 1 | 2020 | 18 | 0.180 |
Why?
| U937 Cells | 1 | 2020 | 14 | 0.180 |
Why?
| Etoposide | 5 | 2009 | 72 | 0.180 |
Why?
| K562 Cells | 1 | 2020 | 42 | 0.180 |
Why?
| Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.180 |
Why?
| Kidney Diseases | 2 | 2020 | 214 | 0.180 |
Why?
| NIH 3T3 Cells | 1 | 2020 | 52 | 0.180 |
Why?
| Mammals | 1 | 2020 | 58 | 0.180 |
Why?
| MCF-7 Cells | 1 | 2020 | 69 | 0.180 |
Why?
| Practice Guidelines as Topic | 1 | 2023 | 449 | 0.180 |
Why?
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.180 |
Why?
| Protein C | 2 | 2011 | 18 | 0.180 |
Why?
| Leukemia, Plasma Cell | 1 | 2020 | 33 | 0.180 |
Why?
| Myelodysplastic Syndromes | 3 | 2007 | 81 | 0.170 |
Why?
| beta 2-Microglobulin | 5 | 2008 | 38 | 0.170 |
Why?
| HEK293 Cells | 1 | 2020 | 224 | 0.170 |
Why?
| Busulfan | 1 | 2019 | 19 | 0.170 |
Why?
| Cisplatin | 6 | 2009 | 278 | 0.170 |
Why?
| HeLa Cells | 1 | 2020 | 260 | 0.170 |
Why?
| Atrial Fibrillation | 1 | 2022 | 183 | 0.170 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 107 | 0.170 |
Why?
| Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.170 |
Why?
| Epigenesis, Genetic | 2 | 2020 | 378 | 0.170 |
Why?
| Imaging, Three-Dimensional | 2 | 2017 | 153 | 0.160 |
Why?
| Genome-Wide Association Study | 1 | 2020 | 166 | 0.160 |
Why?
| Healthcare Disparities | 1 | 2022 | 268 | 0.160 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 10 | 0.160 |
Why?
| Fractures, Compression | 1 | 2018 | 17 | 0.160 |
Why?
| Predictive Value of Tests | 4 | 2009 | 905 | 0.160 |
Why?
| Spleen | 1 | 2019 | 172 | 0.160 |
Why?
| Fibrinolysis | 2 | 2009 | 5 | 0.160 |
Why?
| Phosphotransferases | 1 | 2018 | 16 | 0.160 |
Why?
| Genomic Instability | 2 | 2016 | 93 | 0.150 |
Why?
| Blood Coagulation Factors | 2 | 2009 | 17 | 0.150 |
Why?
| Antineoplastic Agents, Alkylating | 6 | 2008 | 74 | 0.150 |
Why?
| Cytokines | 3 | 2007 | 613 | 0.150 |
Why?
| Bacteremia | 1 | 2019 | 92 | 0.150 |
Why?
| Adipocytes | 1 | 2018 | 121 | 0.150 |
Why?
| Gene Rearrangement | 1 | 2018 | 74 | 0.150 |
Why?
| Cell Line | 1 | 2020 | 1021 | 0.150 |
Why?
| Cluster Analysis | 4 | 2012 | 235 | 0.150 |
Why?
| Metaphase | 4 | 2016 | 44 | 0.150 |
Why?
| Hexokinase | 1 | 2017 | 17 | 0.150 |
Why?
| Heparin, Low-Molecular-Weight | 2 | 2007 | 20 | 0.140 |
Why?
| Ultrasonography, Doppler | 2 | 2007 | 42 | 0.140 |
Why?
| Renal Insufficiency | 4 | 2010 | 109 | 0.140 |
Why?
| Fibrinolytic Agents | 2 | 2007 | 125 | 0.130 |
Why?
| Clonal Evolution | 1 | 2016 | 56 | 0.130 |
Why?
| Calcium | 1 | 2018 | 400 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 180 | 0.130 |
Why?
| Tumor Burden | 3 | 2020 | 131 | 0.130 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2017 | 203 | 0.130 |
Why?
| Gene Expression | 1 | 2018 | 609 | 0.130 |
Why?
| Disease Models, Animal | 4 | 2016 | 1458 | 0.130 |
Why?
| Genes, Neoplasm | 1 | 2015 | 30 | 0.130 |
Why?
| Multivariate Analysis | 7 | 2021 | 581 | 0.130 |
Why?
| Immunotherapy | 2 | 2016 | 240 | 0.130 |
Why?
| Bone Marrow Transplantation | 4 | 2022 | 116 | 0.130 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2020 | 485 | 0.130 |
Why?
| Gene Dosage | 1 | 2015 | 78 | 0.120 |
Why?
| Salvage Therapy | 6 | 2006 | 139 | 0.120 |
Why?
| Incidence | 2 | 2009 | 1006 | 0.120 |
Why?
| Algorithms | 1 | 2018 | 618 | 0.120 |
Why?
| Osteoclasts | 3 | 2022 | 428 | 0.110 |
Why?
| Cystatin M | 2 | 2024 | 20 | 0.110 |
Why?
| Case-Control Studies | 4 | 2011 | 1126 | 0.110 |
Why?
| Altitude | 1 | 2013 | 16 | 0.110 |
Why?
| Chromosomes, Human, Pair 11 | 3 | 2020 | 54 | 0.110 |
Why?
| Janus Kinase 2 | 1 | 2013 | 26 | 0.110 |
Why?
| Cross-Sectional Studies | 3 | 2023 | 1554 | 0.110 |
Why?
| Tomography, X-Ray Computed | 2 | 2017 | 1161 | 0.110 |
Why?
| STAT3 Transcription Factor | 2 | 2010 | 81 | 0.110 |
Why?
| Bone Density Conservation Agents | 2 | 2010 | 74 | 0.110 |
Why?
| Protein-Tyrosine Kinases | 3 | 2018 | 95 | 0.110 |
Why?
| Models, Biological | 1 | 2016 | 723 | 0.110 |
Why?
| Creatinine | 2 | 2010 | 141 | 0.100 |
Why?
| Mice, Inbred C57BL | 1 | 2018 | 1819 | 0.100 |
Why?
| Cytogenetic Analysis | 6 | 2014 | 82 | 0.100 |
Why?
| Viremia | 1 | 2012 | 22 | 0.100 |
Why?
| Clone Cells | 2 | 2023 | 78 | 0.100 |
Why?
| Cytomegalovirus Infections | 1 | 2012 | 35 | 0.100 |
Why?
| Models, Genetic | 2 | 2016 | 170 | 0.100 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2012 | 44 | 0.100 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2012 | 43 | 0.100 |
Why?
| Viper Venoms | 1 | 2011 | 7 | 0.100 |
Why?
| Drug Evaluation, Preclinical | 1 | 2012 | 143 | 0.100 |
Why?
| Epidemiologic Methods | 2 | 2008 | 49 | 0.100 |
Why?
| NF-kappa B | 2 | 2018 | 315 | 0.090 |
Why?
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 6 | 0.090 |
Why?
| Arsenicals | 1 | 2010 | 14 | 0.090 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 20 | 0.090 |
Why?
| Oxides | 1 | 2010 | 18 | 0.090 |
Why?
| Mutation Rate | 2 | 2021 | 36 | 0.090 |
Why?
| Granulocyte Colony-Stimulating Factor | 2 | 2008 | 61 | 0.090 |
Why?
| Hypercalcemia | 1 | 2010 | 33 | 0.090 |
Why?
| Transplantation, Homologous | 4 | 2003 | 138 | 0.090 |
Why?
| Cyclophosphamide | 4 | 2003 | 166 | 0.090 |
Why?
| Antineoplastic Agents, Hormonal | 2 | 2007 | 48 | 0.090 |
Why?
| Janus Kinase 1 | 1 | 2010 | 17 | 0.090 |
Why?
| Anemia | 1 | 2010 | 67 | 0.090 |
Why?
| MAP Kinase Kinase 1 | 1 | 2010 | 23 | 0.090 |
Why?
| Administration, Oral | 2 | 2009 | 434 | 0.090 |
Why?
| Cyclin-Dependent Kinases | 1 | 2010 | 28 | 0.090 |
Why?
| Proteinuria | 1 | 2010 | 39 | 0.090 |
Why?
| Alleles | 2 | 2021 | 251 | 0.090 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 83 | 0.090 |
Why?
| Genomics | 2 | 2023 | 285 | 0.090 |
Why?
| Diphosphonates | 1 | 2010 | 90 | 0.090 |
Why?
| Lorazepam | 1 | 2009 | 12 | 0.080 |
Why?
| Anesthesia, Local | 1 | 2009 | 15 | 0.080 |
Why?
| Hyperhomocysteinemia | 1 | 2009 | 29 | 0.080 |
Why?
| Receptors, Retinoic Acid | 1 | 2009 | 23 | 0.080 |
Why?
| Oxycodone | 1 | 2009 | 27 | 0.080 |
Why?
| Dose-Response Relationship, Drug | 3 | 2008 | 1378 | 0.080 |
Why?
| Prednisone | 1 | 2009 | 101 | 0.080 |
Why?
| Tretinoin | 1 | 2009 | 53 | 0.080 |
Why?
| Hemostatic Techniques | 1 | 2009 | 28 | 0.080 |
Why?
| Plasma Exchange | 1 | 2009 | 23 | 0.080 |
Why?
| Histones | 2 | 2021 | 313 | 0.080 |
Why?
| Vasculitis | 1 | 2008 | 29 | 0.080 |
Why?
| Vincristine | 3 | 2003 | 88 | 0.080 |
Why?
| Syndecan-1 | 3 | 2021 | 72 | 0.080 |
Why?
| Transcription Factors | 2 | 2023 | 564 | 0.080 |
Why?
| Biopsy | 3 | 2018 | 590 | 0.080 |
Why?
| Drug Therapy, Combination | 1 | 2009 | 381 | 0.080 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 110 | 0.080 |
Why?
| Cytogenetics | 1 | 2008 | 23 | 0.080 |
Why?
| Carrier Proteins | 1 | 2010 | 306 | 0.080 |
Why?
| Bone Development | 1 | 2009 | 64 | 0.080 |
Why?
| Radiopharmaceuticals | 2 | 2021 | 208 | 0.080 |
Why?
| Pain Measurement | 1 | 2009 | 240 | 0.080 |
Why?
| Staphylococcal Infections | 2 | 2019 | 269 | 0.080 |
Why?
| Platelet Aggregation | 1 | 2008 | 71 | 0.080 |
Why?
| Thrombocytopenia | 1 | 2009 | 84 | 0.080 |
Why?
| Double-Blind Method | 1 | 2009 | 688 | 0.080 |
Why?
| Brain Diseases, Metabolic | 1 | 2007 | 5 | 0.070 |
Why?
| Phlebography | 1 | 2007 | 60 | 0.070 |
Why?
| Hyperammonemia | 1 | 2007 | 18 | 0.070 |
Why?
| Myeloma Proteins | 1 | 2007 | 24 | 0.070 |
Why?
| Antimetabolites | 1 | 2006 | 13 | 0.070 |
Why?
| Chi-Square Distribution | 1 | 2007 | 278 | 0.070 |
Why?
| Cell Communication | 2 | 2023 | 69 | 0.070 |
Why?
| Transcriptome | 2 | 2020 | 320 | 0.070 |
Why?
| Partial Thromboplastin Time | 1 | 2006 | 12 | 0.070 |
Why?
| Magnetic Resonance Imaging | 4 | 2007 | 1541 | 0.070 |
Why?
| Osteoprotegerin | 1 | 2006 | 52 | 0.070 |
Why?
| Heterozygote | 1 | 2006 | 81 | 0.070 |
Why?
| Acetaminophen | 1 | 2009 | 283 | 0.070 |
Why?
| Antibiotics, Antineoplastic | 1 | 2006 | 81 | 0.070 |
Why?
| Gastrointestinal Neoplasms | 1 | 2006 | 44 | 0.070 |
Why?
| Models, Statistical | 1 | 2007 | 224 | 0.070 |
Why?
| Pilot Projects | 1 | 2008 | 697 | 0.070 |
Why?
| Age Factors | 3 | 2005 | 1092 | 0.060 |
Why?
| Femur Head Necrosis | 1 | 2005 | 18 | 0.060 |
Why?
| Neovascularization, Physiologic | 1 | 2005 | 68 | 0.060 |
Why?
| Apoptosis | 1 | 2010 | 1112 | 0.060 |
Why?
| Syndrome | 2 | 2019 | 238 | 0.060 |
Why?
| Gene Deletion | 2 | 2003 | 270 | 0.060 |
Why?
| Killer Cells, Natural | 1 | 2024 | 107 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 30 | 0.060 |
Why?
| Glucuronidase | 1 | 2003 | 46 | 0.060 |
Why?
| Demography | 1 | 2024 | 92 | 0.060 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 18 | 0.060 |
Why?
| X-Ray Microtomography | 1 | 2024 | 77 | 0.060 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2024 | 128 | 0.060 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2024 | 53 | 0.060 |
Why?
| DNA Methylation | 2 | 2020 | 550 | 0.060 |
Why?
| Immunosuppressive Agents | 1 | 2005 | 222 | 0.060 |
Why?
| DNA, Neoplasm | 2 | 2020 | 147 | 0.060 |
Why?
| Antibodies | 1 | 2024 | 154 | 0.060 |
Why?
| Discitis | 1 | 2003 | 9 | 0.050 |
Why?
| Oligonucleotide Array Sequence Analysis | 4 | 2006 | 411 | 0.050 |
Why?
| Myeloproliferative Disorders | 1 | 2003 | 28 | 0.050 |
Why?
| Antigens, CD34 | 1 | 2003 | 66 | 0.050 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| Platelet Count | 3 | 2008 | 72 | 0.050 |
Why?
| Tumor Cells, Cultured | 3 | 2010 | 468 | 0.050 |
Why?
| Patients | 1 | 2022 | 49 | 0.050 |
Why?
| Geography | 1 | 2022 | 60 | 0.050 |
Why?
| Rats | 1 | 2009 | 3299 | 0.050 |
Why?
| Leukemia, Myeloid | 1 | 2002 | 43 | 0.050 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2022 | 33 | 0.050 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2022 | 51 | 0.050 |
Why?
| Drug Interactions | 1 | 2002 | 208 | 0.050 |
Why?
| Patient Selection | 1 | 2023 | 253 | 0.050 |
Why?
| Chromosome Disorders | 1 | 2002 | 35 | 0.050 |
Why?
| United States Food and Drug Administration | 1 | 2022 | 91 | 0.050 |
Why?
| Oncogenes | 1 | 2021 | 57 | 0.050 |
Why?
| Phylogeny | 1 | 2022 | 234 | 0.050 |
Why?
| Enzyme Inhibitors | 1 | 2004 | 386 | 0.050 |
Why?
| Hypothyroidism | 1 | 2002 | 54 | 0.050 |
Why?
| Central Nervous System Neoplasms | 1 | 2002 | 64 | 0.050 |
Why?
| RANK Ligand | 1 | 2022 | 179 | 0.050 |
Why?
| Transcriptional Activation | 1 | 2021 | 121 | 0.050 |
Why?
| Cohort Studies | 2 | 2020 | 1422 | 0.050 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 92 | 0.050 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 106 | 0.050 |
Why?
| Chromatin | 1 | 2021 | 152 | 0.050 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 225 | 0.050 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 66 | 0.050 |
Why?
| Cyclin D2 | 1 | 2020 | 20 | 0.050 |
Why?
| Aneuploidy | 1 | 2020 | 16 | 0.050 |
Why?
| Pyrimidines | 1 | 2022 | 193 | 0.050 |
Why?
| Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2002 | 254 | 0.050 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2020 | 31 | 0.050 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2020 | 33 | 0.050 |
Why?
| Histone Code | 1 | 2020 | 32 | 0.050 |
Why?
| Cyclin D1 | 1 | 2020 | 56 | 0.050 |
Why?
| ras Proteins | 1 | 2020 | 64 | 0.050 |
Why?
| Genome, Human | 1 | 2021 | 111 | 0.050 |
Why?
| Longitudinal Studies | 2 | 2016 | 695 | 0.040 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2020 | 75 | 0.040 |
Why?
| Protein Kinase Inhibitors | 1 | 2022 | 206 | 0.040 |
Why?
| Transcriptional Elongation Factors | 1 | 2020 | 18 | 0.040 |
Why?
| Postoperative Complications | 1 | 2007 | 996 | 0.040 |
Why?
| Genetic Loci | 1 | 2020 | 49 | 0.040 |
Why?
| Health Status Disparities | 1 | 2022 | 194 | 0.040 |
Why?
| RNA, Messenger | 3 | 2010 | 1108 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 213 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2020 | 176 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 170 | 0.040 |
Why?
| Neoplastic Stem Cells | 2 | 2015 | 103 | 0.040 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2019 | 26 | 0.040 |
Why?
| Computational Biology | 1 | 2020 | 216 | 0.040 |
Why?
| Pseudomonas Infections | 1 | 2019 | 48 | 0.040 |
Why?
| Proline | 1 | 2018 | 30 | 0.040 |
Why?
| Bone Marrow Cells | 2 | 2014 | 190 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 428 | 0.040 |
Why?
| Recombinant Proteins | 2 | 2010 | 487 | 0.040 |
Why?
| Fluorescent Dyes | 1 | 2018 | 106 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 475 | 0.040 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 51 | 0.040 |
Why?
| Proteolysis | 1 | 2018 | 95 | 0.040 |
Why?
| Oncogene Proteins, Fusion | 1 | 2018 | 58 | 0.040 |
Why?
| Extracellular Matrix | 1 | 2018 | 111 | 0.040 |
Why?
| Kidney Function Tests | 1 | 2017 | 49 | 0.040 |
Why?
| Cell Movement | 1 | 2018 | 249 | 0.040 |
Why?
| False Positive Reactions | 1 | 2017 | 62 | 0.040 |
Why?
| Glomerular Filtration Rate | 1 | 2017 | 111 | 0.040 |
Why?
| Amino Acid Sequence | 1 | 2018 | 586 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 509 | 0.030 |
Why?
| Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| Cell Survival | 2 | 2010 | 602 | 0.030 |
Why?
| Genes, p53 | 1 | 2016 | 51 | 0.030 |
Why?
| Mice, SCID | 2 | 2009 | 176 | 0.030 |
Why?
| Glycolysis | 1 | 2016 | 70 | 0.030 |
Why?
| Chromosome Mapping | 2 | 2006 | 156 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 106 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 140 | 0.030 |
Why?
| Serum Albumin | 2 | 2008 | 58 | 0.030 |
Why?
| Syndecans | 2 | 2006 | 34 | 0.030 |
Why?
| Proteoglycans | 2 | 2006 | 80 | 0.030 |
Why?
| Drug Monitoring | 1 | 2015 | 78 | 0.030 |
Why?
| Cells, Cultured | 1 | 2018 | 1581 | 0.030 |
Why?
| Myocardium | 1 | 2017 | 438 | 0.030 |
Why?
| Interspersed Repetitive Sequences | 1 | 2014 | 8 | 0.030 |
Why?
| Karyotype | 1 | 2014 | 18 | 0.030 |
Why?
| Proportional Hazards Models | 2 | 2006 | 410 | 0.030 |
Why?
| Membrane Glycoproteins | 2 | 2006 | 246 | 0.030 |
Why?
| Transplantation Chimera | 2 | 2003 | 15 | 0.030 |
Why?
| Neoplasm Staging | 2 | 2007 | 738 | 0.030 |
Why?
| Infusions, Intravenous | 2 | 2003 | 213 | 0.030 |
Why?
| RNA Interference | 1 | 2013 | 179 | 0.030 |
Why?
| Cytomegalovirus | 1 | 2012 | 27 | 0.030 |
Why?
| Viral Load | 1 | 2012 | 77 | 0.030 |
Why?
| Virus Activation | 1 | 2012 | 32 | 0.030 |
Why?
| Graft vs Host Disease | 2 | 2003 | 75 | 0.020 |
Why?
| United States | 1 | 2022 | 4874 | 0.020 |
Why?
| Interferon Regulatory Factor-1 | 1 | 2010 | 14 | 0.020 |
Why?
| Cell Growth Processes | 1 | 2010 | 22 | 0.020 |
Why?
| Antiviral Agents | 1 | 2012 | 173 | 0.020 |
Why?
| CDC2-CDC28 Kinases | 1 | 2010 | 12 | 0.020 |
Why?
| Femur | 1 | 2010 | 133 | 0.020 |
Why?
| Long-Term Care | 1 | 2010 | 52 | 0.020 |
Why?
| Peripheral Nervous System Diseases | 1 | 2010 | 57 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2010 | 215 | 0.020 |
Why?
| Down-Regulation | 1 | 2010 | 349 | 0.020 |
Why?
| Bone Diseases, Metabolic | 1 | 2010 | 74 | 0.020 |
Why?
| Cell Transformation, Neoplastic | 1 | 2010 | 179 | 0.020 |
Why?
| Abnormalities, Multiple | 1 | 2010 | 167 | 0.020 |
Why?
| Protein Isoforms | 1 | 2009 | 119 | 0.020 |
Why?
| Ploidies | 1 | 2008 | 11 | 0.020 |
Why?
| Ligands | 1 | 2009 | 205 | 0.020 |
Why?
| Rabbits | 1 | 2009 | 374 | 0.020 |
Why?
| Hemoglobins | 1 | 2008 | 107 | 0.020 |
Why?
| Polyethylene Glycols | 1 | 2008 | 93 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 595 | 0.020 |
Why?
| Age Distribution | 1 | 2007 | 168 | 0.020 |
Why?
| Ammonia | 1 | 2007 | 72 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2008 | 143 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1043 | 0.020 |
Why?
| Mass Screening | 1 | 2010 | 346 | 0.020 |
Why?
| Multigene Family | 1 | 2006 | 56 | 0.020 |
Why?
| Blood Proteins | 1 | 2007 | 82 | 0.020 |
Why?
| Bone Density | 1 | 2009 | 379 | 0.020 |
Why?
| Cyclin D | 1 | 2006 | 18 | 0.020 |
Why?
| Brain | 2 | 2007 | 1328 | 0.020 |
Why?
| Cyclins | 1 | 2006 | 38 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2006 | 45 | 0.020 |
Why?
| Evidence-Based Medicine | 1 | 2007 | 247 | 0.020 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2007 | 185 | 0.020 |
Why?
| Radiography | 1 | 2007 | 491 | 0.020 |
Why?
| Coculture Techniques | 1 | 2006 | 146 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2006 | 157 | 0.020 |
Why?
| Neoplasms, Experimental | 1 | 2006 | 114 | 0.020 |
Why?
| Interferon-alpha | 1 | 2005 | 48 | 0.020 |
Why?
| Survivors | 1 | 2006 | 125 | 0.020 |
Why?
| Databases, Factual | 1 | 2007 | 657 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2006 | 550 | 0.010 |
Why?
| Monosomy | 1 | 2003 | 5 | 0.010 |
Why?
| Odds Ratio | 1 | 2005 | 546 | 0.010 |
Why?
| Trisomy | 1 | 2003 | 31 | 0.010 |
Why?
| History, 21st Century | 1 | 2003 | 55 | 0.010 |
Why?
| Endothelial Growth Factors | 1 | 2003 | 9 | 0.010 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2003 | 15 | 0.010 |
Why?
| Lymphokines | 1 | 2003 | 20 | 0.010 |
Why?
| Fusion Proteins, bcr-abl | 1 | 2003 | 20 | 0.010 |
Why?
| Stem Cell Factor | 1 | 2003 | 7 | 0.010 |
Why?
| History, 20th Century | 1 | 2003 | 99 | 0.010 |
Why?
| Confidence Intervals | 1 | 2003 | 156 | 0.010 |
Why?
| Lymphocyte Transfusion | 1 | 2003 | 10 | 0.010 |
Why?
| Probability | 1 | 2003 | 164 | 0.010 |
Why?
| Interphase | 1 | 2003 | 13 | 0.010 |
Why?
| Diploidy | 1 | 2003 | 26 | 0.010 |
Why?
| Leukocyte Count | 1 | 2003 | 72 | 0.010 |
Why?
| Back Pain | 1 | 2003 | 39 | 0.010 |
Why?
| Interferons | 1 | 2002 | 38 | 0.010 |
Why?
| Sex Factors | 1 | 2005 | 697 | 0.010 |
Why?
| Cell Count | 1 | 2003 | 149 | 0.010 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 105 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 2003 | 377 | 0.010 |
Why?
| Thyroid Function Tests | 1 | 2002 | 24 | 0.010 |
Why?
| Thyrotropin | 1 | 2002 | 48 | 0.010 |
Why?
| Prevalence | 1 | 2005 | 951 | 0.010 |
Why?
| Tissue Donors | 1 | 2003 | 113 | 0.010 |
Why?
| Neutrophils | 1 | 2003 | 148 | 0.010 |
Why?
| Fatal Outcome | 1 | 2002 | 195 | 0.010 |
Why?
| Cell Division | 1 | 2002 | 295 | 0.010 |
Why?
| Reoperation | 1 | 2003 | 454 | 0.010 |
Why?
| Acute Disease | 1 | 2002 | 368 | 0.010 |
Why?
| Up-Regulation | 1 | 2002 | 453 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2003 | 747 | 0.010 |
Why?
|
|
Zangari's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|